Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will be used for the development of IVMED-85, an investigational eyedrop formulation containing copper intended for treatment of pediatric myopia. IVMED-85 will be the first eye drop inducing both scleral and corneal crosslinking for myopia control.
Lead Product(s): IVMED-85
Therapeutic Area: Ophthalmology Product Name: IVMED-85
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: iVeena
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 26, 2023
Details:
Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.
Lead Product(s): PTG-630
Therapeutic Area: Neurology Product Name: PTG-630
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Praetego
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding March 01, 2023
Details:
TRE-515 is a novel first-in-class drug, which has been shown to prevent demyelination, and even facilitate remyelination, in multiple demyelinating disease mouse models. Furthermore, the FDA has designated TRE-515 an Orphan Drug in the treatment of ON.
Lead Product(s): TRE-515
Therapeutic Area: Oncology Product Name: TRE-515
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Trethera
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 19, 2022
Details:
Infusions of purified IL-27 regulatory B cells (I27-Breg ) reduced symptoms in mouse models of multiple sclerosis (MS) and the eye disease autoimmune uveitis. The research suggests the cells may play a role in future human therapies.
Lead Product(s): I27-Breg
Therapeutic Area: Ophthalmology Product Name: I27-Breg
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021